Who
Karen L. Smith
Director
Company insider
Files Form 4 as: Director, Context Therapeutics; Director, Skye Bioscience; Director, Sangamo Therapeutics; Director, Aurinia Pharmaceuticals; Director, Talaris Therapeutics; Chief Medical Officer, Quince Therapeutics; Director, Antares Pharma; Director, Acceleron Pharma.
In numbers
- Trades disclosed
- 120
- Buys
- 3
- Sells
- 3
- Bought
- $250K
- Sold
- $2.9M
- Companies
- 11
- Companies where not an officer
- 8
- First trade
- 11 May 2015
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | Sangamo Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,500 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,641 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,135 at $0.00 | filing |
| 11 Nov 2024filed 12 Nov 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $44K5,241 at $8.43 | filing |
| 8 Nov 2024filed 12 Nov 2024 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,913 at $0.00 | filing |
| 8 Nov 2024filed 12 Nov 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —17,913 | filing |
| 28 Oct 2024filed 30 Oct 2024 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 4 Sep 2024filed 5 Sep 2024 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,315 at $0.00 | filing |
| 2 Jul 2024filed 5 Jul 2024 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Sangamo Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Above Fifty Day Moving Average – Time to Sell?AUPH · tickerreport.com · 17 Oct 2026Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026Critical Analysis: vTv Therapeutics (NASDAQ:VTVT) and Jazz Pharmaceuticals (NASDAQ:JAZZ)JAZZ · tickerreport.com · 12 Oct 2026Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'JAZZ · cnbc.com · 10 Oct 2026Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Crosses Above 50-Day Moving Average – Here's What HappenedAUPH · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Karen L. Smith; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.